Related Experiment Video

Updated: Aug 8, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

CYP induction-mediated drug interactions: in vitro assessment and clinical implications

Jiunn H Lin1

  • 1Department of Preclinical Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania, USA. jiunn_lin@merck.com

Pharmaceutical Research
|May 24, 2006
PubMed

Insights

Cytochrome P450 (CYP) induction can reduce drug effectiveness and increase toxicity. Developing new drug candidates that avoid potent CYP induction is crucial for safer drug therapies and minimizing drug interactions.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Toxicology

Background:

  • Cytochrome P450 (CYP) induction poses significant risks in clinical settings and the pharmaceutical industry.
  • Key concerns include reduced therapeutic efficacy of co-administered drugs and increased toxicity from reactive metabolites.
  • CYP induction represents a metabolic liability, necessitating the development of drug candidates with minimal induction potential.

Purpose of the Study:

  • To review the molecular mechanisms underlying CYP induction.
  • To discuss the clinical implications of CYP induction, encompassing pharmacokinetic and pharmacodynamic effects.
  • To explore factors influencing CYP induction and the extrapolation of in vitro data to in vivo scenarios.

Main Methods:

  • Literature review of molecular mechanisms of CYP induction.
  • Analysis of clinical implications, including pharmacokinetic and pharmacodynamic consequences.
  • Discussion of factors affecting CYP induction and in vitro-to-in vivo extrapolation.

Main Results:

  • CYP induction can lead to significant drug-drug interactions, impacting patient safety and treatment outcomes.
  • Understanding molecular mechanisms is key to predicting and mitigating CYP induction.
  • Early assessment of CYP induction potential in drug discovery is vital for selecting safer drug candidates.

Conclusions:

  • Minimizing CYP induction is a critical goal in drug development to prevent adverse drug reactions and ensure therapeutic efficacy.
  • Comprehensive evaluation of CYP induction, from molecular mechanisms to clinical implications, is essential.
  • Integrating CYP induction assessment early in the drug discovery process aids in the selection of viable drug candidates.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...